Get started
Author

Nuria Juanpere-Rodero

Observed names: J. Nuria, N Juanpere, N. Juanpere, N. Juanpere Rodero, N. Juanpere-Rodero, Nuria Juanpere, Nuria Juanpere Rodero, Nuria Juanpere‐Rodero, Núria JUANPERE, Núria Juanpere, Núria Juanpere Rodero, Núria Juanpere-Rodero, Rodero Nuria Juanpere
Observed institutions: Universitat Autònoma de Barcelona, University of Tsukuba, University of Freiburg, Carol Davila University of Medicine and Pharmacy, Universitat Pompeu Fabra, Lister Hospital, West China Hospital of Sichuan University, Hospices Civils de Lyon, Hôpital Edouard Herriot, Institut Municipal d'Assistència Sanitària, Hospital Del Mar, Parc de Salut, Municipal Institute for Medical Research, Hospital del Mar Research Institute, Centro de Investigación Biomédica en Red de Cáncer, Red de Investigación en Servicios de Salud en Enfermedades Crónicas
ORCID: 0000-0003-4954-9494
Observed ORCID: 0000-0003-4954-9494
OpenAlex ID: A5102860860
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
2011 · Irene Puga, Montserrat Cols, et al. · Nature Immunology · 760
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
2013 · Cristina Balbás-Martínez, Ana Sagrera, et al. · Nature Genetics · 278
Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic Study
2006 · Antonio Salar, Nuria Juanpere, et al. · The American Journal of Surgical Pathology · 137
Treponema pallidum distribution patterns in mucocutaneous lesions of primary and secondary syphilis: an immunohistochemical and ultrastructural study
2009 · Gemma Martín-Ezquerra, Alex Fernandez-Casado, et al. · Human Pathology · 117
Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases
2018 · Maria Alejo, Laia Alemany, et al. · Papillomavirus Research · 83
PDF
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer
2020 · Joaquim Bellmunt, Jaegil Kim, et al. · Cancer Research · 79
FGFR3 mutations in prostate cancer: association with low-grade tumors
2009 · Silvia Hernández, Silvia de Muga, et al. · Modern Pathology · 79
PDF
Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas
2010 · Silvia de Muga, Silvia Hernández, et al. · Modern Pathology · 73
Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels
2015 · Alba Font‐Tello, Núria Juanpere, et al. · The Prostate · 68
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
2012 · Nuria Juanpere, Laia Agell, et al. · Human Pathology · 66
Quality of life in patients with non–muscle-invasive bladder cancer: One-year results of a multicentre prospective cohort study
2014 · Stefanie Schmidt, Albert Francés, et al. · Urologic Oncology Seminars and Original Investigations · 58
A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer
2012 · Laia Agell, Silvia Hernández, et al. · American Journal Of Pathology · 57
PDF
Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse
2014 · Marta Riera, Eva Márquez, et al. · PLoS ONE · 53
PDF
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
2010 · Laia Agell, Silvia Hernández, et al. · Modern Pathology · 52
PDF
Gene expression dynamics after murine pancreatitis unveils novel roles for Hnf1α in acinar cell homeostasis
2011 · Xavier Molero, Eva Cristina Vaquero, et al. · Gut · 49
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations
2008 · Laia Agell, Silvia Hernández, et al. · Modern Pathology · 45
PDF
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities
2019 · Neus Martínez-Bosch, Alejo Rodriguez-Vida, et al. · Nature Reviews Urology · 35
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2019 · Anna Hernández-Prat, Alejo Rodriguez-Vida, et al. · Molecular Cancer Research · 31
Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status
2019 · Raquel Albero-González, Silvia Hernández-Llodrà, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 27
A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non–muscle‐invasive urothelial cell carcinoma
2011 · Ana B. Galván, Marta Salido, et al. · Cancer Cytopathology · 27
PDF
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
2017 · Silvia Hernández-Llodrà, Nuria Juanpere, et al. · Oncotarget · 23
PDF
Isolated Conjunctival Lichen Planus: A Diagnostic Challenge
2011 · Eduardo Rozas Muñoz, Maria Estela Martínez-Escala, et al. · Archives of Dermatology · 23
The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
2023 · Lilian Marie Boll, Júlia Perera-Bel, et al. · Scientific Reports · 21
PDF
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG‐rearranged prostate cancer
2019 · Silvia Hernández‐Llodrà, Laura Segalés, et al. · The Prostate · 21
FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression
2017 · Josep Lloreta, Alba Font-Tello, et al. · Human Pathology · 21
Works count: 118
Citation count: 2,609
H-index: 22
I10-index: 41
Year
Topic
Type